| 1.4 -0.02 (-1.41%) | 06-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
AVROBIO, Inc. is a biotechnology firm in the clinical development stage, dedicated to advancing gene therapies. The company specializes in an ex vivo lentiviral-based approach, aiming to address rare genetic conditions worldwide through a single therapeutic administration. Their innovative methodology involves collecting hematopoietic stem cells directly from patients. These cells are then genetically engineered using a lentiviral vector, which introduces functional copies of the specific gene that is deficient or defective in the patient's condition. Among its pipeline, AVROBIO's lead candidate is AVR-RD-01, designed for the treatment of Fabry disease. The company's therapeutic portfolio also includes AVR-RD-02, currently undergoing Phase 1/2 clinical trials for Type 1 Gaucher disease, alongside AVR-RD-03 for Pompe disease, AVR-RD-04 for cystinosis, and AVR-RD-05 for Hunter syndrome. Additionally, AVR-RD-06 is in preclinical development, targeting Type 3 Gaucher disease. Established in 2015, AVROBIO maintains its corporate headquarters in Cambridge, Massachusetts.
Wed, 31 Jan 2024
Avrobio’s road ends in reverse merger with Tim Springer-backed startup - biopharmadive.com
Tue, 30 Jan 2024
AVROBIO and Tectonic Therapeutic Announce Merger - Business Wire
Wed, 12 Jul 2023
AVROBIO to Explore Strategic Alternatives - Business Wire
Wed, 12 Jul 2023
Avrobio halts gene therapy research and considers a sale - biopharmadive.com
Mon, 22 May 2023
AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million - Business Wire
Mon, 22 May 2023
Novartis buys rare disease gene therapy from Avrobio - biopharmadive.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|